Genetic association between TNF-α -308 G>A polymorphism and longitudinal weight change during clozapine treatment

Human Psychopharmacology

Volumn 25, Issue 4, 2010, Pages 303-309

  Wang, Ying Chieh ^a,b   Bai, Ya Mei ^c,d   Chen, Jen Yeu ^a   Lin, Chao Cheng ^e   Lai, I Ching ^b,f   Liou, Ying Jay ^c,d  

^a YULI VETERANS HOSPITAL   (Taiwan)

^b TZU CHI UNIVERSITY   (Taiwan)

^c TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^d NATIONAL YANG MING UNIVERSITY   (Taiwan)

^e NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^f BUDDHIST TZU CHI GENERAL HOSPITAL   (Taiwan)

Author keywords

Body weight; Clozapine; Pharmacogenetic study; Schizophrenia; TNF

Indexed keywords

CLOZAPINE; LITHIUM; NEUROLEPTIC AGENT; TUMOR NECROSIS FACTOR ALPHA; VALPROIC ACID;

ADULT; AGE; ALLELE; ARTICLE; BODY MASS; CONTROLLED STUDY; FEMALE; GENDER; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HOMOZYGOTE; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SCHIZOPHRENIA; SIDE EFFECT; TREATMENT DURATION; TREATMENT RESPONSE; WEIGHT CHANGE; WEIGHT GAIN;

ADULT; ANTIPSYCHOTIC AGENTS; CLOZAPINE; FEMALE; HUMANS; MALE; MIDDLE AGED; PHARMACOGENETICS; POLYMORPHISM, GENETIC; SCHIZOPHRENIA; TUMOR NECROSIS FACTOR-ALPHA; WEIGHT GAIN;

EID: 77953937453     PISSN: 08856222     EISSN: 10991077     Source Type: Journal    
DOI: 10.1002/hup.1122     Document Type: Article

References (34)

1. Allison DB, Mentore JL, Heo M, et al. 1999. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatr 156: 1686-1696.
2. Bai YM, Lin CC, Chen JY, Lin CY. 1999. Weight gain among patients on clozapine. Psychiatr Serv 50: 704-705.
3. Bai YM, Lin CC, Chen JY, Lin CY, Su TP, Chou P. 2006. Association of initial antipsychotic response to clozapine and long-term weight gain. Am J Psychiatr 163: 1276-1279.
4. Basile VS, Masellis M, McIntyre RS, Meltzer HY, Lieberman JA, Kennedy JL. 2001. Genetic dissection of atypical antipsychotic-induced weight gain: novel preliminary data on the pharmacogenetic puzzle. J Clin Psychiatr 62 (Suppl 23): 45-66.
5. Bruun JM, Pedersen SB, Kristensen K, Richelsen B. 2002. Opposite regulation of interleukin-8 and tumor necrosis factor-alpha by weight loss. Obes Res 10: 499-506.
6. Bullo-Bonet M, Garcia-Lorda P, Lopez-Soriano FJ, Argiles JM, Salas-Salvado J. 1999. Tumour necrosis factor, a key role in obesity? FEBS Lett 451: 215-219.
7. Correll CU, Malhotra AK. 2004. Pharmacogenetics of antipsychotic-induced weight gain. Psychopharmacology (Berl) 174: 477-489.
8. Covell NH, Weissman EM, Essock SM. 2004. Weight gain with clozapine compared to first generation antipsychotic medications. Schizophr Bull 30: 229-240.
9. Dandona P, Weinstock R, Thusu K, Abdel-Rahman E, Aljada A, Wadden T. 1998. Tumor necrosis factor-alpha in sera of obese patients: fall with weight loss. J Clin Endocrinol Metab 83: 2907-2910.
10. De Luca V, Mueller DJ, de Bartolomeis A, Kennedy JL. 2007. Association of the HTR2C gene and antipsychotic induced weight gain: a metaanalysis. Int J Neuropsychopharmacol 10: 697-704.
11. Fountaine RJ, Taylor AE, Mancuso JP, et al. 2010. Increased Food Intake and Energy Expenditure Following Administration of Olanzapine to Healthy Men. Obesity (Silver Spring) [Epub ahead of print].
12. Haack M, Hinze-Selch D, Fenzel T, et al. 1999. Plasma levels of cytokines and soluble cytokine receptors in psychiatric patients upon hospital admission: effects of confounding factors and diagnosis. J Psychiatr Res 33: 407-418.
13. Henderson DC, Cagliero E, Gray C, et al. 2000. Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: A five-year naturalistic study. Am J Psychiatr 157: 975-981.
14. Himmerich H, Koethe D, Schuld A, Yassouridis A, Pollmacher T. 2005. Plasma levels of leptin and endogenous immune modulators during treatment with carbamazepine or lithium. Psychopharmacology (Berl) 179: 447-451.
15. Hinze-Selch D, Deuschle M, Weber B, Heuser I, Pollmacher T. 2000. Effect of coadministration of clozapine and fluvoxamine versus clozapine monotherapy on blood cell counts, plasma levels of cytokines and body weight. Psychopharmacology (Berl) 149: 163-169.
16. Hotamisligil GS, Arner P, Caro JF, Atkinson RL, Spiegelman BM. 1995. Increased adipose tissue expression of tumor necrosis factor-alpha in human obesity and insulin resistance. J Clin Invest 95: 2409-2415.
17. Kern PA, Ranganathan S, Li C, Wood L, Ranganathan G. 2001. Adipose tissue tumor necrosis factor and interleukin-6 expression in human obesity and insulin resistance. Am J Physiol Endocrinol Metab 280: E745-E751.
18. Kern PA, Saghizadeh M, Ong JM, Bosch RJ, Deem R, Simsolo RB. 1995. The expression of tumor necrosis factor in human adipose tissue. Regulation by obesity, weight loss, and relationship to lipoprotein lipase. J Clin Invest 95: 2111-2119.
19. Kluge M, Schuld A, Schacht A, et al. 2009. Effects of clozapine and olanzapine on cytokine systems are closely linked to weight gain and drug-induced fever. Psychoneuroendocrinology 34: 118-128.
20. Kras KM, Hausman DB, Martin RJ. 2000. Tumor necrosis factor-alpha stimulates cell proliferation in adipose tissue-derived stromal-vascular cell culture: promotion of adipose tissue expansion by paracrine growth factors. Obes Res 8: 186-193.
21. Kraus T, Haack M, Schuld A, Hinze-Selch D, Koethe D, Pollmacher T. 2002. Body weight, the tumor necrosis factor system, and leptin production during treatment with mirtazapine or venlafaxine. Pharmacopsychiatry 35: 220-225.
22. Masellis M, Basile VS, Ozdemir V, Meltzer HY, Macciardi FM, Kennedy JL. 2000. Pharmacogenetics of antipsychotic treatment: lessons learned from clozapine. Biol Psychiatr 47: 252-266.
23. Pollmacher T, Hinze-Selch D, Mullington J. 1996. Effects of clozapine on plasma cytokine and soluble cytokine receptor levels. J Clin Psychopharmacol 16: 403-409.
24. Reynolds GP, Kirk SL. 2010. Metabolic side effects of antipsychotic drug treatment-pharmacological mechanisms. Pharmacol Ther 125: 169-179.
25. Reynolds GP, Zhang ZJ, Zhang XB. 2002. Association of antipsychotic drug-induced weight gain with a 5-HT2C receptor gene polymorphism. Lancet 359: 2086-2087.
26. Schuld A, Kraus T, Haack M, Hinze-Selch D, Kuhn M, Pollmacher T. 2000. Plasma levels of cytokines and soluble cytokine receptors during treatment with olanzapine. Schizophr Res 43: 164-166.
27. Shirts BH, Bamne M, Kim JJ, et al. 2006. A comprehensive genetic association and functional study of TNF in schizophrenia risk. Schizophr Res 83: 7-13.
28. Sookoian SC, Gonzalez C, Pirola CJ. 2005. Meta-analysis on the G-308A tumor necrosis factor alpha gene variant and phenotypes associated with the metabolic syndrome. Obes Res 13: 2122-2131.
29. Tandon R, Fleischhacker WW. 2005. Comparative efficacy of antipsychotics in the treatment of schizophrenia: a critical assessment. Schizophr Res 79: 145-155.
30. Templeman LA, Reynolds GP, Arranz B, San L. 2005. Polymorphisms of the 5-HT2C receptor and leptin genes are associated with antipsychotic drug-induced weight gain in Caucasian subjects with a first-episode psychosis. Pharmacogenet Genom 15: 195-200.
31. Tsai SJ, Hong CJ, Yu YW, Lin CH, Liu LL. 2003. No association of tumor necrosis factor alpha gene polymorphisms with schizophrenia or response to clozapine. Schizophr Res 65: 27-32.
32. Umbricht DS, Pollack S, Kane JM. 1994. Clozapine and weight gain. J Clin Psychiatr 55 (Suppl B): 157-160.
33. Wilson AG, Symons JA, McDowell TL, McDevitt HO, Duff GW. 1997. Effects of a polymorphism in the human tumor necrosis factor alpha promoter on transcriptional activation. Proc Natl Acad Sci USA 94: 3195-3199.
34. Zai G, Muller DJ, Volavka J, et al. 2006. Family and case-control association study of the tumor necrosis factor-alpha (TNF-alpha) gene with schizophrenia and response to antipsychotic medication. Psychopharmacology (Berl) 188: 171-182.